Navigation Links
NYSCF Fellow lead author on study that creates blood vessel cells from stem cells
Date:1/21/2010

NEW YORK, NY (January 21) - New York Stem Cell Foundation (NYSCF)-Druckenmiller Fellow, Daylon James, PhD, of Weill Cornell Medial College, is lead author on a study defining conditions for generating a plentiful supply of endothelial (vessel lining) cells that are suitable for therapeutic use. Dr. James and his colleagues created a human embryonic stem cell (hESC) "reporter" line that can be used to measure endothelial cell production and activity.

The study, Expansion and maintenance of human embryonic stem cellderived endothelial cells by TGFβ inhibition is Id1 dependent, was published in the online edition of Nature Biotechnology on January 17th, 2010, and will also appear in the journal's print edition. In addition to Dr. James, whose work is funded by NYSCF, contributors to the study also included NYSCF-Druckenmiller Fellows, Drs. Gabsang Lee and Marco Seandel.

Using the reporter line, Dr. James and his colleagues were able to monitor the emergence of endothelial cells in live cultures, and screen for small bioactive molecules that increased their yield. By this method, they were able to indentify a compound that robustly increased the amount of endothelial cells produced. This work establishes a standard methodology for generating functional endothelial cells from hESCs using conditions that are suited to clinical application. These cells can now be routinely and economically produced on scales that make pre-clinical assessment of their efficacy practical in large animal models of vascular disease.

"We are very proud of Dr. James. These findings bring us closer to having functional endothelial cells available for studying vascular disease," says Susan L. Solomon, NYSCF's founder and CEO.

As advancements in induced pluripotent stem (iPS) cell technology continue, hESC research like that of Dr. James is essential for the field of stem cell research. Embryonic stem cells are still the gold standard fo
'/>"/>

Contact: Ruth Jarmul
rjarmul@nyscf.org
212-787-4111
New York Stem Cell Foundation
Source:Eurekalert

Page: 1 2

Related biology news :

1. IGERT fellows to design biodevices using flexible electronics
2. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
3. UC Riverside biologist receives prestigious MacArthur Fellowship
4. Entomological Society of America recognizes 2007 fellows and honorary members
5. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young investigators
6. Pew Institute for Ocean Science awards 5 fellowships in support of global marine conservation
7. 2008 Pew Fellowship in marine conservation awarded to UM Rosenstiels Dr. Andrew Baker
8. Dr. Andrew Constable awarded 2008 Pew Fellowship in marine conservation
9. 2008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila
10. 2008 Pew Fellowship in Marine Conservation awarded to Fan Meng; first Chinese fellow
11. 2008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... from the Wildlife Conservation Society, have announced that yellow fever ... in northeastern Argentina, a finding that underscores the importance of ... health of people and wild nature are so closely linked. ... American Journal of Primatology focuses on yellow fever outbreaks that ...
... Recent petitions from several African nations to ,downlist, the ... adequate monitoring of the impact of ivory sales or ... published today by an international group of researchers including ... sale of stockpiled ivory from South Africa, Botswana, Namibia ...
... first time, researchers have been able to confine and study ... photosynthesis, without having to pin it down so tightly as ... application to proteins of a recently developed technique, two Stanford ... behavior of the molecule for more than one second, a ...
Cached Biology News:Yellow fever strikes monkey populations in South America 2Boost ivory trade monitoring and enforcement before allowing one-off sales: UBC researcher 2Behavior of single protein observed in unprecedented detail by Stanford chemists 2Behavior of single protein observed in unprecedented detail by Stanford chemists 3
(Date:7/30/2015)... Senomyx , Inc. (NASDAQ: SNMX ), a leading ... and commercialize novel flavor ingredients for the food, beverage, ... the second quarter 2015. "Moving into ... to achieve our commercial and financial goals," stated John ... "Since our last quarterly earnings report, our two partners ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... applications and designed for continuous operation up to 1500 bar. The sanitary design ... efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... GREENWOOD VILLAGE, Colo., Dec. 22, 2011 Ampio Pharmaceuticals, ... or the "Company"), a company that discovers and develops ... entities ("NMEs"), today announced notification of the granting of ... METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM". ...
... Mich., Dec. 22, 2011  Neogen Corporation (NASDAQ: NEOG ... of FY 2012, which ended Nov. 30, increased 2.2% from ... the quarter was $5,237,000, or $0.22 per share, compared to ... $0.26 per share. Year-to-date revenues for the first ...
... 2011 Epitomics, Inc., a California based biotech ... a Star Program in collaboration with the University ... application of a new, advanced antibody assay technique, ... measurements of antibody-antigen interactions. Over the course of ...
Cached Biology Technology:Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 2Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 3Neogen Reports Second Quarter Results 2Neogen Reports Second Quarter Results 3Neogen Reports Second Quarter Results 4Neogen Reports Second Quarter Results 5Neogen Reports Second Quarter Results 6Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions 2
... CAST Equine EIA Principle: ... LTD4 and LTE4 are products ... 5-lipoxygenase and glutathione-S-transferase. In the ... "Slow Reacting Substances of Anaphylaxis ...
... contain the basic components and protocol ... ELISA plates for quantitation of a ... cell culture supernate. Every Screening Set ... Standard (5 individual standards), Streptavidin-HRP, TMB ...
... degradation is critical to the maintenance ... regulatory proteins as important and diverse ... heat shock and stress response, antigen ... and ion channels, cell cycle regulation, ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Biology Products: